The Human Leukocyte Differentiation Antigen workshop Ⅱ (HLDA2), held in Boston, USA, in 1984. The purpose of HLDA2 was to continue to define clusters of antibodies identifying myeloid-associated antigens. This workshop also examined antibodies thought to react with natural killer (NK) cells, and with a group of heterodimeric molecules associated with specific leukocyte functions and referred to as the LFA family.
One hundred and twenty antibodies were submitted by 41 laboratories in the form of ascites fluid in most cases. Of these, four were of insufficient quantity to be analyzed and 116 antibodies were analyzed in detail, two of which were withdrawn. Each participating laboratory evaluated the panel of antibodies using one or more of the six myeloid protocols. In addition, CD antigens thought to have anti-NK and LFA activity were designated. The results of serologic and cluster analysis will be discussed later in this chapter, while data obtained from functional, biochemical, and phylogeny studies will be presented in individual reports in this volume.
|CD16a||FcγRIIIA, FCGR3A, FCG3, FCGR3, IGFR3||Low affinity Fc receptor. Mediates phagocytosis and antibody-dependent T-cell-mediated cytotoxicity|
|CD16b||FcγRIIIB, FCGR3B, FCG3, FCGR3, IGFR3||Low affinity Fc receptor|
|CD18||Integrin β2, ITGB2, MFI7||Adhesion, cell signaling|
|CD19||B4, Leu-12||Regulates B-cell development, activation and differentiation. Signal transduction|
|CD20||B1, Bp35, MS4A1||B-cell activation and proliferation|
|CD21||C3DR, CR2, EBV-R||Signal transduction. Regulator of complement activation|
|CD22||BL-CAM, Siglec-2, Leu-14||B-cell adhesion and signal transduction|
|CD23||FcεRII, BLAST-2, FCER2, CLEC4J||Low affinity receptor for IgE, ligand for CD19, CD21 and CD81. Key molecule for B-cell activation and growth|
|CD24||BA-1, Nectadrin||Regulation of B-cell proliferation and differentiation|
|CD25||Tac, p55, IL2RA||Receptor for IL2|
|CD26||DPP IV, DPP4, ADABP, ADCP2||Exoprotease. HIV pathogenesis|